Imtiaz A. Samjoo

Dr. Imtiaz A. Samjoo

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
ISImtiaz A. Samjoo
Imtiaz A. Samjoo
EWEvelyn Worthington
Evelyn Worthington
CDChristopher Drudge
Christopher Drudge
MZMelody Zhao
Melody Zhao
CCChris Cameron
Chris Cameron
NANicholas Adlard
Nicholas Adlard
Background: The Association of British Neurologists (ABN) 2015 guidelines suggested classifying multiple sclerosis therapies according to their average relapse reduction. We sought to classify newer therapies (cladribine, ocrelizumab, ofatumumab, ozanimod) based on these guidelines. Materials & methods: Therapies were classified by using direct comparative trial results as per ABN guidelines and generating classification probabilities for each therapy based on comparisons versus placebo in a network meta-analysis for annualized relapse rate. Results: For both approaches, cladribine and ofatumumab were classified as high efficacy. Ocrelizumab and ozanimod (1.0 mg) were classified as moderate or high efficacy depending on the approach used. Conclusion: Cladribine and ofatumumab have an efficacy comparable with therapies classified in the ABN guidelines as high efficacy.

1 June 2021 in The Breast
Verified
Journal Article
Open access
ESElizabeth M. Salvo
Elizabeth M. Salvo
ARAbril Oliva Ramirez
Abril Oliva Ramirez
JCJenilee Cueto
Jenilee Cueto
ELErnest H. Law
Ernest H. Law
ASAaron Situ
Aaron Situ
ISImtiaz A. Samjoo
Imtiaz A. Samjoo
A systematic review and meta-analysis was conducted to assess breast cancer (BC) outcomes among patients with early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) BC, receiving adjuvant endocrine therapy. Randomized controlled trials (RCTs) and real-world evidence (RWE) studies were identified using Ovid MEDLINE®, Embase, and Evidence-Based Medicine Reviews. Clinical and methodological similarities including alignment of outcome definitions with standardized definitions for efficacy endpoints criteria were assessed to evaluate feasibility of conducting a meta-analysis. Where feasible, 5-year probabilities of BC recurrence or death were estimated using a Bayesian hierarchical arm-based model. Of 21 included studies, 8 RCTs and 4 RWE studies reported outcome data of interest. There was heterogeneity in outcome reporting, as well as variation in recurrence risk amongst studies with aligned reporting. Of the 12 studies, 10 were considered for inclusion in a meta-analysis of BC recurrence or death. Only a subgroup analysis of node-positive patients (3 studies; n = 7307) was deemed feasible. The 5-year probability of BC recurrence or death was 17.2% (95% credible interval: 14.6%-20.3%). Although studies reporting recurrence outcomes were limited, there remains a high risk of BC recurrence, especially among node-positive patients. Approximately 1 in 6 women with node-positive HR+/HER2- early-stage BC receiving endocrine therapy experience recurrence or death within 5-years of initiating treatment, suggesting a need for novel treatments for this population.

1 December 2020 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Closed access
ISImtiaz A. Samjoo
Imtiaz A. Samjoo
EWEvelyn Worthington
Evelyn Worthington
CDChristopher Drudge
Christopher Drudge
MZMelody Zhao
Melody Zhao
CCChris Cameron
Chris Cameron
NANicholas Adlard
Nicholas Adlard
Aim: To compare the efficacy of ofatumumab to other disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS). Materials & methods: A network meta-analysis was conducted to determine the relative effect of ofatumumab on annualized relapse rate and confirmed disability progression at 3 months and 6 months. Results: For each outcome, ofatumumab was as effective as other highly efficacious monoclonal antibody DMTs (i.e., alemtuzumab, natalizumab and ocrelizumab). Conclusion: Ofatumumab offers beneficial outcomes for RMS by reducing relapse and disability progression risk.

1 July 2023 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Open access
ISImtiaz A. Samjoo
Imtiaz A. Samjoo
CDChristopher Drudge
Christopher Drudge
SWSarah Walsh
Sarah Walsh
STSantosh Tiwari
Santosh Tiwari
RBRóisín Brennan
Róisín Brennan
JBJudit Banhazi
Judit Banhazi
Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs for annualised relapse rate (ARR) and time to 3-month and 6-month confirmed disability progression (3mCDP and 6mCDP) were conducted. Results: For each outcome, the three most efficacious treatments versus placebo were monoclonal antibody (mAb) therapies: alemtuzumab, ofatumumab, and ublituximab for ARR; alemtuzumab, ocrelizumab, and ofatumumab for 3mCDP; and alemtuzumab, natalizumab, and either ocrelizumab or ofatumumab (depending on the CDP definition used for included ofatumumab trials) for 6mCDP. Conclusion: The most efficacious DMTs for RMS were mAb therapies. Of the newer therapies, only ublituximab ranked among the three most efficacious treatments (for ARR).

23 July 2021 in Current Medical Research and Opinion
Verified
Journal Article
Open access
TMTom Martin
Tom Martin
SUSaad Z. Usmani
Saad Z. Usmani
JSJordan M. Schecter
Jordan M. Schecter
MVMartin Vogel
Martin Vogel
CJCarolyn C. Jackson
Carolyn C. Jackson
ISImtiaz A. Samjoo
Imtiaz A. Samjoo
This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300–460 × 106 CAR-positive T-cells for the ...

5 June 2024 in Value in Health
Verified
Journal Article
Open access
STShiro Tanaka
Shiro Tanaka
AIAtaru Igarashi
Ataru Igarashi
RMRaf De Moor
Raf De Moor
NLNan Li
Nan Li
MHMariko Hirozane
Mariko Hirozane
CCChris Cameron
Chris Cameron
Controls and governance over the methodology and reporting of indirect treatment comparisons (ITCs) have been introduced to minimize bias and ensure scientific credibility and transparency in healthcare decision-making. The objective of this study was to highlight ITC techniques that are key to conducting objective and analytically-sound analyses, and to ascertain circumstantial suitability of ITCs as a source of comparative evidence for healthcare interventions. Ovid MEDLINE® was searched from January 2010 through August 2023 to identify publicly available ITC-related documents (i.e., guidelines and best practices) in the English language. This was supplemented with hand-searches of websites of various international organizations, regulatory agencies, and reimbursement agencies of Europe, North America, and Asia-Pacific. The jurisdiction-specific ITC methodology and reporting recommendations were reviewed. Sixty-eight guidelines from 10 authorities worldwide were included for synthesis. Many of the included guidelines were updated within the last five years and commonly cited the absence of direct comparative studies as primary justification for employing ITCs. Most jurisdictions favored population-adjusted or anchored ITC techniques opposed to naïve comparisons. Recommendations on the reporting and presentation of these ITCs varied across authorities; however, there was some overlap among the key elements. Given the challenges of conducting head-to-head randomized controlled trials, comparative data from ITCs offer valuable insights into clinical effectiveness. As such, multiple ITC guidelines have emerged worldwide. According to the most recent versions of the guidelines, the suitability and subsequent acceptability of the ITC technique employed depends on the data sources, available evidence, and magnitude of benefit/uncertainty.